JP2020529440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529440A5 JP2020529440A5 JP2020505905A JP2020505905A JP2020529440A5 JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5 JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541260P | 2017-08-04 | 2017-08-04 | |
| US62/541,260 | 2017-08-04 | ||
| PCT/US2018/044973 WO2019028234A1 (en) | 2017-08-04 | 2018-08-02 | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529440A JP2020529440A (ja) | 2020-10-08 |
| JP2020529440A5 true JP2020529440A5 (enExample) | 2021-09-09 |
Family
ID=65230918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505905A Pending JP2020529440A (ja) | 2017-08-04 | 2018-08-02 | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10813918B2 (enExample) |
| EP (1) | EP3648762A4 (enExample) |
| JP (1) | JP2020529440A (enExample) |
| KR (1) | KR20200047557A (enExample) |
| CN (1) | CN111201022A (enExample) |
| AU (1) | AU2018309049A1 (enExample) |
| CA (1) | CA3071939A1 (enExample) |
| IL (1) | IL272414A (enExample) |
| MX (1) | MX2020001342A (enExample) |
| WO (1) | WO2019028234A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| CA3078652A1 (en) | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| KR20210110585A (ko) | 2018-11-21 | 2021-09-08 | 썰테고 테라퓨틱스 아이엔씨. | 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌 |
| US11364228B2 (en) | 2019-12-18 | 2022-06-21 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| WO2022269439A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| EP4511030A4 (en) * | 2022-04-20 | 2026-04-01 | Aclipse Two Inc | TREATMENT OF GASTROINTESTINAL DISEASES |
| EP4770634A1 (en) * | 2023-08-29 | 2026-07-08 | Aclipse Two Inc. | Pharmaceutical composition for use in the disease treatments |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| ZA200607427B (en) * | 2004-04-02 | 2009-02-25 | Lundbeck & Co As H | Treatment of impaired respiratory function with gaboxadol |
| JP2007530604A (ja) * | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
| EP1863808A1 (en) * | 2005-03-18 | 2007-12-12 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7635710B2 (en) * | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| DK2083811T3 (en) | 2006-11-22 | 2017-01-30 | Clinical Res Ass Llc | PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM |
| TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
| CN107050456B (zh) * | 2010-09-28 | 2022-08-12 | 加利福尼亚大学董事会 | 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合 |
| EP2741779A1 (en) * | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| EP3795156A1 (en) | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Pharmaceutical composition for treating angelman syndrome |
| EP3154979B1 (en) | 2014-06-12 | 2018-03-07 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
| EP3236994A1 (en) * | 2014-12-23 | 2017-11-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Alpha-cell re-generation combined with conversion to beta cells |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| CN108024997A (zh) | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
-
2018
- 2018-08-02 CA CA3071939A patent/CA3071939A1/en active Pending
- 2018-08-02 MX MX2020001342A patent/MX2020001342A/es unknown
- 2018-08-02 CN CN201880065399.8A patent/CN111201022A/zh active Pending
- 2018-08-02 JP JP2020505905A patent/JP2020529440A/ja active Pending
- 2018-08-02 US US16/053,081 patent/US10813918B2/en not_active Expired - Fee Related
- 2018-08-02 AU AU2018309049A patent/AU2018309049A1/en not_active Abandoned
- 2018-08-02 WO PCT/US2018/044973 patent/WO2019028234A1/en not_active Ceased
- 2018-08-02 EP EP18840846.2A patent/EP3648762A4/en not_active Withdrawn
- 2018-08-02 KR KR1020207006304A patent/KR20200047557A/ko not_active Withdrawn
-
2020
- 2020-02-02 IL IL272414A patent/IL272414A/en unknown
- 2020-10-08 US US17/066,389 patent/US11291658B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP6066144B2 (ja) | 併用医薬 | |
| CA2724133C (en) | Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine | |
| TW202202139A (zh) | 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重 | |
| KR20260036616A (ko) | Glp1r 작용제의 치료적 용도 | |
| JP2018509419A5 (enExample) | ||
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| TW202435860A (zh) | 用於治療疼痛的ｒ—ｍｄｍａ | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| CN1921881A (zh) | 羟基化氨基酸用于治疗糖尿病的用途 | |
| JP6692903B2 (ja) | 高血糖症を処置する方法 | |
| JP6550160B2 (ja) | 糖尿病及び関連症状の治療のための方法及び組成物 | |
| TW201210586A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
| WO2006116470A1 (en) | Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment | |
| JPWO2007007757A1 (ja) | ＰＰＡＲγアゴニストを含有する医薬組成物 | |
| CA3100635A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| WO2011002012A1 (ja) | Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬 | |
| US7608625B2 (en) | Method for treating bruxism and bruxism-related diseases | |
| JP2006519881A5 (enExample) | ||
| JP2009513593A (ja) | 糖尿病の治療 | |
| JP2017128545A (ja) | 併用医薬 | |
| WO2012133693A1 (ja) | 糖尿病治療用の組合せ医薬 | |
| JP2005314380A5 (enExample) | ||
| JP2006063074A5 (enExample) | ||
| BR112019005039B1 (pt) | Método de redução dos efeitos colaterais associados à tireoide |